COHANCE

** Shares of Cohance Lifescieces COHA.NS fall 4.8% to 919.60 rupees

** About 34.2 mln shares traded in a block deal, at a discount of 6.2% to last close, according to LSEG data

** Advent unit Jusmiral Holdings plans to offload up to 8.9% stake in Cohance Lifesciences via block deals worth about 30.7 billion rupees (~$350 mln), CNBC reports, which Reuters could not confirm

** Report adds shares being offered at floor price of 900 rupees apiece, 6.9% discount to last close

** COHA down 19.2% YTD

($1 = 87.9625 Indian rupees)

(Reporting by Urvi Dugar)

(([email protected]))

Sept 11 (Reuters) - Cohance Lifesciences Ltd COHA.NS:

• COHANCE LIFESCIENCES LTD - USFDA COMPLETES CGMP AUDIT AT ANDHRA PRADESH FACILITY

• COHANCE LIFESCIENCES LTD - INSPECTION CONCLUDED WITH ZERO FORM 483 OBSERVATIONS

Source text: ID:nBSEbgnF80

Further company coverage: COHA.NS

(([email protected];;))

** IIFL Capital initiates coverage on contract research and drug manufacturing firm Cohance Lifesciences COHA.NS with "buy" and PT of 1,140 rupees

** Brokerage says COHA's acquisitions of drugmakers NJ Bio and Sapala strengthen its position in the fast-growing market of antibody drug conjugates (ADC), also known as "guided missile drugs" as they directly target cancer cells, minimizing damage to healthy cells

** Jefferies' PT highest among six analysts tracking COHA - data compiled by LSEG

** Revenue contribution from COHA'S niche tech, which includes these new molecules, is expected to double from 17% in FY25 to over 35% by FY30 - Jefferies

** Avg rating of analysts on COHA at "strong buy"; median PT is 1,235 rupees - data compiled by LSEG

** YTD, COHA stock down 23.4%

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

** Shares of Cohance Lifesciences COHA.NS decline 6.8% to 918.7 rupees; on track for biggest intraday pct drop since August 2022

** Pharma co posts a 35% drop in first-quarter consol net profit; rev jumps ~13% but expenses are also up 22%

** About 327,000 shares traded, 1.7x the 30-day avg

** Year-to-date, stock down ~19%

** Despite Q1 results, stock rated "strong buy" on avg, median PT is 1,235 rupees

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

Aug 13 (Reuters) - Cohance Lifesciences Ltd COHA.NS:

• COHANCE LIFESCIENCES JUNE-QUARTER NET PROFIT 525.7 MILLION RUPEES

• COHANCE LIFESCIENCES JUNE-QUARTER REVENUE FROM OPERATIONS 4.84 BILLION RUPEES

Source text: ID:nNSE8VynZb

Further company coverage: COHA.NS

(([email protected];))

June 20 (Reuters) - Cohance Lifesciences Ltd COHA.NS:

• TO SELL CR BIO UNIT FOR 160 MILLION RUPEES

• SALE EXPECTED TO COMPLETE IN Q2 FY2026

Source text: ID:nBSEbdc5cH

Further company coverage: COHA.NS

(([email protected];;))

April 25 (Reuters) - Suven Pharmaceuticals Ltd SUVH.NS:

• SUVEN PHARMACEUTICALS - TO ISSUE 11 CO SHARES FOR EVERY 295 COHANCE LIFESCIENCES SHARES

Source text: ID:nNSEV6RDB

Further company coverage: SUVH.NS

(([email protected];))

** Suven Pharmaceuticals SUVH.NS rises 2.1% to 1,074 rupees after dropping 6.4% in the last two sessions amid a broader market drop triggered by Trump tariffs

** Day's rise comes after Goldman Sachs starts coverage with "buy", sets PT at 1,350 rupees - potential upside of 28.2% in the next 12 months

** Brokerage expects structural growth rebound for co starting this fiscal year, driven by sustained traction for its top five drugs, new drug approvals

** YTD, stock falls 7.5%

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

Jan 1 (Reuters) - Suven Pharmaceuticals Ltd SUVH.NS:

• SUVEN PHARMACEUTICALS LTD - CASPER PHARMA DISSOLVED AND AMALGAMATED WITH SUVEN PHARMACEUTICALS

Source text: ID:nBSE8lpNr3

Further company coverage: SUVH.NS

(([email protected];;))

Sept 19 (Reuters) - Suven Pharmaceuticals Ltd SUVH.NS:

• VAIDHEESH ANNASWAMY DECIDED TO STEP DOWN AS EXECUTIVE CHAIRPERSON

• NAMES VIVEK SHARMA AS EXECUTIVE CHAIRMAN

Source text for Eikon: ID:nNSE3WRgk5

Further company coverage: SUVH.NS

(([email protected];;))

Aug 9 (Reuters) - Suven Pharmaceuticals Ltd SUVH.NS:

• SUVEN PHARMACEUTICALS LTD JUNE-QUARTER CONSOL NET PROFIT 607.7 MILLION RUPEES

• SUVEN PHARMACEUTICALS LTD JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 2.31 BILLION RUPEES

Source text for Eikon: [ID:]

Further company coverage: SUVH.NS

(([email protected];))

** Shares of Suven Pharmaceuticals Ltd SUVH.NS up 4.9% at 700.50 rupees

** Contract drug manufacturer acquires smaller peer Sapala Organics for 2.3 billion rupees ($27.5 million) to bolster its contract and development manufacturing services (CDMO) business

** Earlier this year, SUVH merged with another CDMO firm, Cohance

** Sapala's "robust" margin profile and strong presence in Japan among key reasons for acquisition - SUVH presentation

** Over 305,000 shares traded, 1.6x 30-day avg volume

** Stock trims YTD losses to 4.3%, trails pharma stocks' .NIPHARM ~18% rise

($1 = 83.5300 Indian rupees)

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

June 13 (Reuters) - Suven Pharmaceuticals Ltd SUVH.NS:

• EXECUTED DEFINITIVE AGREEMENTS FOR ACQUIRING 100% OF SHARES IN SAPALA ORGANICS

• DEAL FOR 2.3 BILLION RUPEES

• CO AGREED TO INITIALLY ACQUIRE 67.5% BY WAY OF SECONDARY TRANSFER FROM SAPALA ORGANICS EXISTING SHAREHOLDERS

Source text for Eikon: ID:nBSE3qYcqh

Further company coverage: SUVH.NS

(([email protected];;))

** Shares of Suven Pharmaceuticals Ltd SUVH.NS fall as much as 4.8% to 602 rupees, their lowest since March 18

** Co reported a ~57% fall in its fourth-quarter consol net profit to 533.7 mln rupees ($6.4 mln), while rev fell 31.5% Y/Y

** "Revenue growth was impacted by shipment delays caused by client-specific inventory de-stocking," co said in a statement

** Stock on track to fall for the second straight day

** More than 581,000 shares traded as of 11:56 a.m. IST, 4.8x their 30-day moving avg

** SUVH last down 1.6%, adding to YTD losses of ~14.4%

($1 = 83.2875 Indian rupees)

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))

** Shares of Suven Pharmaceuticals SUVH.NS up 12% in heavy volumes

** Stock eyes best day in more than 3 years

** Contract drug maker said it will merge with privately held Cohance Lifesciences in an all-stock deal to boost its contract and development manufacturing services (CDMO) business

** Trading volume tops 3 mln shares, more than 10x the 30-day moving avg

** Thursday's gains trim YTD losses to 2.5%; stock surged 46% in 2023

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

Feb 29 (Reuters) - Suven Pharmaceuticals Ltd SUVH.NS:

• SUVEN PHARMACEUTICALS - SHAREHOLDERS OF COHANCE WILL BE ISSUED SHARES OF CO AT RATIO OF 11 SHARES OF CO FOR EVERY 295 SHARES OF COHANCE

• SUVEN PHARMACEUTICALS - NEW SHARES OF SUVEN ISSUED WILL BE TRADED ON NSE AND BSE

• SUVEN PHARMACEUTICALS - ADVENT ENTITIES SHALL OWN ABOUT 66.7% AND PUBLIC SHAREHOLDERS WILL HOLD ABOUT 33.3% OF COMBINED ENTITY

• SUVEN PHARMACEUTICALS - TRANSACTION EXPECTED TO CONCLUDE OVER NEXT 12-15 MONTHS

Source text for Eikon: ID:nBSE76tfM9

Further company coverage: SUVH.NS

(([email protected];))

** Shares of Suven Pharmaceuticals SUVH.NS up 1.4% at 673.85 rupees

** Co says two facilities have completed U.S. FDA inspections and no Form 483 was issued; form is issued when violations are observed, per FDA website

** Stock on track to end four-day losing streak if trend holds

** Stock surges as much as 5.2% to its highest level in a month

** Since slumping on Feb. 6 after Q3 profit drop, stock has regained 9.4%

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))

Feb 23 (Reuters) - Suven Pharmaceuticals Ltd SUVH.NS:

• SUVEN PHARMACEUTICALS LTD - COMPLETION OF PRE-APPROVAL INSPECTIONS (PAI) AND GOOD MANUFACTURING PRACTICES (GMP) INSPECTIONS BY USFDA

• SUVEN PHARMACEUTICALS LTD - NO FORM 483 HAS BEEN ISSUED AS A RESULT OF THE INSPECTION

• SUVEN PHARMACEUTICALS LTD - API FACILITIES IN PASHAMYLARA COMPLETED PRE- APPROVAL INSPECTIONS AND GOOD MANUFACTURING PRACTICES INSPECTIONS

• SUVEN PHARMACEUTICALS LTD - INSPECTIONS BY US FOOD & DRUG ADMINISTRATION

Source text for Eikon: ID:nBSE62GhBW

Further company coverage: SUVH.NS

(([email protected];;))

** Shares of Suven Pharmaceuticals SUVH.NS fall as much as 10.4% to 585.2 rupees, lowest level since Nov. 20

** The pharma co said on Monday its Q3 net profit more than halved to 523.6 mln rupees ($6.3 mln), rev from ops slipped ~39% Y/Y

** More than 665,000 shares change hands, 3.5x its 30-day avg

** Stock fell ~7% in January, snapping eight consecutive monthly gains

($1 = 83.0380 Indian rupees)

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

Dec 21 (Reuters) - Suven Pharmaceuticals Ltd SUVH.NS:

• APPOINTMENT OF HIMANSHU AGARWAL AS CHIEF FINANCIAL OFFICER

• SUBBA RAO PARUPALLI WILL CEASE TO BE CFO

Source text for Eikon: [ID:]

Further company coverage: SUVH.NS

(([email protected];))

** Suven Pharmaceuticals SUVH.NS shares 3.6% to 615 rupees, their highest since April 29, 2022

** Stock set for fourth straight day of gains, during which it has risen nearly 6%

** Stock has now gained 8.4% since the company posted results on Nov. 9

** Since then, the stock has also traded above its 50- ,100- and 200-day daily moving averages

** More than 380,000 shares traded by 1.28 p.m. IST, 1.4x the 30-day avg

** Stock up nearly 22% YTD, set for its best on-year gain since listing

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

Nov 9 (Reuters) - Suven Pharmaceuticals Ltd SUVH.NS:

• INDIA'S SUVEN PHARMACEUTICALS LTD SEPT-QUARTER CONSOL NET PROFIT 795.6 MILLION RUPEES VERSUS 720.6 MILLION RUPEES YEAR AGO

• SUVEN PHARMACEUTICALS LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 2.31 BILLION RUPEES VERSUS 2.78 BILLION RUPEES YEAR AGO

Source text for Eikon: [ID:]

Further company coverage: SUVH.NS

(([email protected];))

Sept 29 (Reuters) - Suven Pharmaceuticals Ltd SUVH.NS:

• NAMED VETUKURI VENKATA NAGA KALI VARA PRASADA RAJU AS MD

• NAMED SUDHIR KUMAR SINGH AS CEO

Source text for Eikon: ID:nBSE7tPdp9

Further company coverage: SUVH.NS

(([email protected];))

Sept 26 (Reuters) - Suven Pharmaceuticals Ltd SUVH.NS:

• MINISTRY OF CHEMICALS AND FERTILIZERS GRANTED APPROVAL FOR ACQUISITION OF UP TO 76.1% STAKE IN CO BY BERHYANDA

Source text for Eikon: ID:nBSE4NXqmJ

Further company coverage: SUVH.NS

(([email protected];))

Sept 13 (Reuters) - Suven Pharmaceuticals Ltd SUVH.NS:

• CABINET APPROVES FOREIGN INVESTMENT OF UP TO 95.89 BILLION RUPEES IN SUVEN PHARMACEUTICALS LIMITED - INDIA GOVERNMENT

Source text for Eikon: [ID:]

Further company coverage: SUVH.NS

(([email protected];))

Aug 8 (Reuters) - Suven Pharmaceuticals Ltd SUVH.NS:

• SUVEN PHARMACEUTICALS LTD JUNE-QUARTER CONSOL NET PROFIT 1.21 BILLION RUPEES VERSUS 1.08 BILLION RUPEES

• SUVEN PHARMACEUTICALS LTD JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 3.48 BILLION RUPEES VERSUS 3.39 BILLION RUPEES

Source text for Eikon: ID:nNSE53prfb

Further company coverage: SUVH.NS

(([email protected];))

April 20 (Reuters) - India Government:

• INDIA COMPETITION REGULATOR APPROVES ACQUISITION OF 76.10% STAKE IN SUVEN PHARMACEUTICALS BY BERHYANDA LIMITED

Further company coverage: SUVH.NS

(([email protected];))